Fig. 1

Ocular glymphatic clearance is unaltered in diabetic CD1 mice. (A) Schematic diagram of experimental approach. (B) Representative macroscopic images of optic nerves from control and diabetic mice four months after sham or STZ injection. (C) Total tracer signal over the entire length of the optic nerve at two and four months after onset of STZ-induced diabetes, with subtraction of background fluorescence of the contralateral non-injected control optic nerve (n = 9–10). (D) Plot of total tracer signal (arbitrary units (A.U.)), (E) peak signal intensity (A.U.), and (F) peak signal travel distance (µm). n = 9–10, ns = P > 0.05 between indicated groups by two-way ANOVA with Tukey’s correction (D-F). (G) Representative retina wholemounts imaged by epifluorescent microscopy for quantitation of tracer distribution. White circle– retina center, white arrow– site of intravitreal injection, orange line– example of drawn line ROI. Scale bar 1 mm. (H) Total tracer signal (A.U.) in control and diabetic retinas of the two- and four-month time points for different segments of the retina (distance ascending from retina center in µm). (I) Total tracer signal (A.U.) for whole retinas of two- and four-month diabetic and control mice. H + I) n = 4–7, ns = P > 0.05 between indicated groups by two-way ANOVA with Tukey’s correction. All graphs show mean ± SD